176 related articles for article (PubMed ID: 12488469)
1. Erbitux trial flawed from the beginning, committee finds.
Randal J
J Natl Cancer Inst; 2002 Dec; 94(24):1824-5. PubMed ID: 12488469
[No Abstract] [Full Text] [Related]
2. [Utilizing synergism].
Krankenpfl J; 2005; 43(4-6):145. PubMed ID: 16171088
[No Abstract] [Full Text] [Related]
3. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
Heinemann V; Hoff PM
Oncology; 2010; 79(1-2):118-28. PubMed ID: 21088438
[TBL] [Abstract][Full Text] [Related]
4. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
Longo F; Mansueto G
Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
[No Abstract] [Full Text] [Related]
5. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
6. [Systemic therapy for colorectal cancer].
Pestalozzi BC; Jäger D; Knuth A
Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Moosmann N; Heinemann V
Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C
Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
[TBL] [Abstract][Full Text] [Related]
9. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Rosati G
Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):20-1. PubMed ID: 16265095
[No Abstract] [Full Text] [Related]
10. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
Mahtani RL; Macdonald JS
Oncologist; 2008 Jan; 13(1):39-50. PubMed ID: 18245011
[TBL] [Abstract][Full Text] [Related]
11. Promising drug is victim of bad business.
Dove A
Nat Med; 2002 Mar; 8(3):199. PubMed ID: 11875472
[No Abstract] [Full Text] [Related]
12. ERBITUX as a single agent and in combination in colorectal carcinoma.
Expert Rev Anticancer Ther; 2002 Jun; 2(3):242. PubMed ID: 12113039
[No Abstract] [Full Text] [Related]
13. New treatment options for colorectal cancer.
Erlichman C; Sargent DJ
N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
[No Abstract] [Full Text] [Related]
14. Cetuximab in colon cancer.
Costa AF; Sander GB; Picon PD
N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473024
[No Abstract] [Full Text] [Related]
15. Highlights from: 42nd Annual Meeting of the American Society of Clinical Oncology.
Reddy GK; Guputa M; Tyagi P
Clin Colorectal Cancer; 2006 Sep; 6(3):184-8. PubMed ID: 17026786
[No Abstract] [Full Text] [Related]
16. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Saltz LB
Nat Clin Pract Oncol; 2005 Jan; 2(1):20-1. PubMed ID: 16264850
[No Abstract] [Full Text] [Related]
17. The price tag on progress--chemotherapy for colorectal cancer.
Schrag D
N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
[No Abstract] [Full Text] [Related]
18. Nothing succeeds like failure.
Nat Biotechnol; 2002 Feb; 20(2):101. PubMed ID: 11821837
[No Abstract] [Full Text] [Related]
19. Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancer.
Chu E
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S60-1. PubMed ID: 16336750
[No Abstract] [Full Text] [Related]
20. Biotech firm faces challenges from FDA, falling stock prices.
Reynolds T
J Natl Cancer Inst; 2002 Mar; 94(5):326-8. PubMed ID: 11880468
[No Abstract] [Full Text] [Related]
[Next] [New Search]
